![]() |
市場調查報告書
商品編碼
2149298
免疫學領域生物相似藥市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測Immunology Biosimilars Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
2025年全球免疫生物相似藥市場規模為158億美元,預計將從2026年的182億美元成長至2034年的382.5億美元,預測期內年複合成長率(CAGR)為9.73%。2025年,歐洲以35.69%的市場佔有率引領市場。該市場涵蓋用於治療自體免疫疾病和慢性發炎性疾病(例如類風濕性關節炎、乾癬、乾癬性關節炎克隆氏症、克隆氏症和潰瘍性大腸炎)的生物相似藥。
主要生物製藥專利到期數量不斷增加、監管部門批准的增加、醫生信心的增強以及保險公司降低治療成本的努力,都在推動市場成長。2025年3月,Celltrion在美國推出了STEQEYMA,Ustekinumab單抗生物類似藥,是STELARA的學名藥,擴大了多種慢性發炎性疾病患者獲得生物相似藥的機會。
市場趨勢
人們越來越傾向選擇價格適中的免疫生物製藥產品。
在醫療保健系統中,生物相似藥的應用日益廣泛,目的是擴大患者獲得長期生物製藥治療的機會,同時控制其長期成本。多種生物相似藥的出現加劇了價格競爭,促使醫生和醫療保健機構考慮從原廠生物製藥轉向生物相似藥。2026年1月,百康生物製劑公司宣布推出三款免疫學生物類似藥產品,分別針對trastuzumab/hyaluronidase、Nivolumab和Pembrolizumab,顯示該公司生物相似藥產品系列持續擴展。
市場動態
促進因素 - 專利到期和監理核准增加
生物製藥關鍵免疫學領域壟斷的瓦解為生物相似藥生產商創造了新的機會。Adalimumab、Infliximab、Etanercept和Ustekinumab等已上市的標靶藥物拓展治療選擇並加劇市場競爭。此外,監管部門批准數量的增加也使生產商能夠將生物相似藥推向多個適應症市場。
抑制因素 - 激烈的競爭
成熟的生物相似藥面臨著來自多種針對同一參考生技藥品的產品的競爭。生產商通常透過折扣、回扣、醫院競標和處方藥清單協議等方式競爭。同時,生物相似藥的生產需要複雜的生產流程、品質檢測、法規遵循和藥物安全監測,這給利潤率和商業性永續性帶來了壓力。
市場機會 - 下一代免疫學中的分子
各公司正瞄準新型生物製藥,並將業務拓展至過敏性氣喘、慢性自發性蕁麻疹、鼻息肉、發炎性腸道疾病和幼年型關節炎等適應症。透過掌握這些機會,各公司可以擺脫對競爭激烈、成熟分子藥物的依賴,實現業務多元化,並擴大目標患者群體。
市場挑戰 - 監管和開發的複雜性
開發生物相似藥的公司必須證明其在分析等效性、藥物動力學特性、免疫抗原性、安全性和生產一致性方面具有廣泛的等效性。各國不同的監管要求可能導致研發成本增加和核准時間延長,尤其對於複雜的單株抗體和新一代免疫製劑而言。
The global immunology biosimilars market size was valued at USD 15.80 billion in 2025 and is projected to grow from USD 18.20 billion in 2026 to USD 38.25 billion by 2034, exhibiting a CAGR of 9.73% during the forecast period. Europe dominated the market with a 35.69% market share in 2025. The market comprises biosimilar therapies used for autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Increasing patent expirations of major biologics, regulatory approvals, growing physician confidence, and payer efforts to reduce treatment costs are supporting market growth. In March 2025, Celltrion launched STEQEYMA, an ustekinumab biosimilar to STELARA, in the U.S., expanding access to biosimilar treatment for several chronic inflammatory conditions.
Market Trends
Growing Shift Toward Affordable Immunology Biologics
Healthcare systems are increasingly adopting biosimilars to expand patient access while controlling the cost of long-term biologic treatment. The availability of multiple biosimilar options is increasing price competition and encouraging physicians and healthcare providers to consider switching from reference biologics. In January 2026, Biocon Biologics introduced three immunology biosimilar assets targeting trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, reflecting continued expansion of biosimilar portfolios.
Market Dynamics
Driver - Growing Patent Expirations and Regulatory Approvals
The loss of exclusivity for major immunology biologics is creating opportunities for biosimilar manufacturers. Products targeting established molecules such as adalimumab, infliximab, etanercept, and ustekinumab are expanding treatment options and competition. Increasing regulatory approvals are also allowing manufacturers to commercialize biosimilars across multiple indications.
Restraint - Intense Price Competition
Mature biosimilar molecules face competition from several products targeting the same reference biologic. Manufacturers often compete through discounts, rebates, hospital tenders, and formulary agreements. At the same time, biosimilar production requires complex manufacturing, quality testing, regulatory compliance, and pharmacovigilance, creating pressure on margins and commercial sustainability.
Market Opportunity - Next-Wave Immunology Molecules
Manufacturers are increasingly targeting newer biologics and expanding into indications such as allergic asthma, chronic spontaneous urticaria, nasal polyps, inflammatory bowel disease, and juvenile arthritis. These opportunities can allow companies to diversify beyond highly competitive mature molecules and expand their addressable patient population.
Market Challenge - Regulatory and Development Complexity
Biosimilar developers must demonstrate extensive analytical comparability, pharmacokinetic characteristics, immunogenicity, safety, and manufacturing consistency. Different regulatory requirements across countries can increase development costs and extend approval timelines, particularly for complex monoclonal antibodies and next-generation immunology products.
By Drug Class
The market is segmented into TNF-alpha inhibitors, interleukin inhibitors, B-cell/anti-CD20 therapies, anti-IgE therapies, and others. TNF-alpha inhibitors dominated in 2025, supported by broad use of adalimumab, infliximab, and etanercept across autoimmune diseases and extensive physician familiarity. Anti-IgE therapies are projected to grow at a CAGR of 16.61%.
By Product
The market includes adalimumab, infliximab, etanercept, rituximab, ustekinumab, tocilizumab, omalizumab, golimumab, and other biosimilars. Infliximab biosimilars held the leading position in 2025, supported by extensive clinical use and established physician confidence. Ustekinumab biosimilars are projected to grow at a CAGR of 23.24%.
By Indication
Rheumatology, gastroenterology, dermatology, allergy and clinical immunology, systemic autoimmune diseases and vasculitis, ophthalmic immunology, and others constitute the segments. Rheumatology dominated in 2025, driven by long-term treatment requirements for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory joint disorders. Allergy and clinical immunology is projected to grow at a CAGR of 16.22%.
By Age Group
The market is divided into pediatric and adult. Adults dominated in 2025, reflecting the large population affected by chronic autoimmune and inflammatory conditions requiring long-term biologic treatment. The pediatric segment is projected to grow at a CAGR of 12.73%.
By Route of Administration
Subcutaneous, intravenous, and other routes are covered. Subcutaneous products dominated in 2025, owing to greater convenience and reduced infusion requirements for long-term treatment. The others segment is projected to grow at a CAGR of 8.64%.
By Distribution Channel
The market includes hospital pharmacies, specialty pharmacies, drug stores and retail pharmacies, and online pharmacies. Hospital pharmacies dominated in 2025, supported by institutional procurement, specialist-led treatment, cold-chain requirements, and centralized biosimilar purchasing. Specialty pharmacies are projected to grow at a CAGR of 12.57%.
Europe
Europe dominated the market in 2025 with a market value of USD 5.64 billion and is projected to reach USD 6.31 billion in 2026. Established biosimilar regulations, centralized tendering, physician experience, and healthcare-system efforts to reduce biologic expenditure support regional growth. Germany is projected to reach USD 1.36 billion in 2026, while the U.K. is estimated at USD 0.87 billion.
North America
North America reached USD 4.81 billion in 2025, compared with USD 4.08 billion in 2024. Biosimilar launches, biologic patent expirations, payer pressure, and expanding interchangeability designations are supporting adoption. The U.S. market is estimated at USD 5.13 billion in 2026.
Asia Pacific
Asia Pacific held the third-largest position in 2025 and is projected to reach USD 4.94 billion in 2026. China, Japan, India, and other regional markets benefit from large patient populations, improving biologic access, and expanding biosimilar manufacturing. Japan is estimated at USD 1.04 billion, China at USD 1.17 billion, and India at USD 0.85 billion in 2026.
Latin America and Middle East & Africa
Latin America is estimated to reach USD 0.81 billion in 2026, supported by regulatory approvals and commercialization partnerships. The GCC market is projected to reach USD 0.23 billion, while South Africa is estimated at approximately USD 0.12 billion in 2026.
Competitive Landscape
Key companies include Celltrion, Sandoz, Samsung Bioepis, Biogen, Organon, Amgen, Pfizer, Fresenius Kabi, Biocon Biologics, Alvotech, and STADA Arzneimittel. Companies are focusing on new product launches, regulatory approvals, interchangeability designations, strategic partnerships, manufacturing expansion, and geographic commercialization.
Key Industry Developments
In February 2026, STADA and Bio-Thera Solutions received European Commission marketing authorization for Gotenfia, a golimumab biosimilar. In November 2025, Celltrion received European Commission authorization for the liquid formulation of Remsima IV. In November 2025, Bio-Thera Solutions entered an agreement with Dr. Reddy's Laboratories for a proposed secukinumab biosimilar. In August 2025, Gedeon Richter received European authorization for BAT2206, an ustekinumab biosimilar. In August 2025, Bio-Thera and STADA expanded their biosimilar alliance to include tocilizumab.
Report Coverage
The Immunology Biosimilars Market Report provides comprehensive Market Research Report coverage of market size, market value, Market Share, Market Trends, Market Growth, Market Analysis, Industry Analysis, Market Forecast, regional performance, segmentation, regulatory developments, product launches, pricing dynamics, competitive strategies, partnerships, and acquisitions. The Industry Report evaluates drug class, product, indication, age group, route of administration, and distribution channel while analyzing Market Opportunities and challenges through 2034.
Conclusion
The global immunology biosimilars market is expanding as healthcare systems seek affordable alternatives to high-cost biologic therapies and pharmaceutical companies respond to growing patent expirations. The market size is projected to increase from USD 15.80 billion in 2025 to USD 18.20 billion in 2026 and USD 38.25 billion by 2034. TNF-alpha inhibitors, infliximab biosimilars, rheumatology, adult therapies, subcutaneous products, and hospital pharmacies remain important market segments. Meanwhile, ustekinumab and anti-IgE biosimilars, emerging immunology molecules, expanding interchangeability, and growing adoption in Asia Pacific are creating additional Market Opportunities. Price competition, regulatory complexity, manufacturing requirements, and market-access barriers will continue to influence the Market Outlook through 2034.
Segmentation By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Region
By Drug Class
By Product
By Indication
By Age Group
By Route of Administration
By Distribution Channel
By Region